Announcements Trials
Browse Landscape

Phase

Phase NA 2

Status

Completed 4Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Observational 3Interventional 2

Sponsor

Cancer Type

Gynecologic 13Tumor-Agnostic 12Gastrointestinal 11Thoracic 8Genitourinary 8Other hematologic neoplasm 6Breast 6NET 5Lymphoid 5Endocrine 5Dermatologic 5Head & Neck 4Plasma cell 3Other solid neoplasm 3CNS 3Sarcoma 2Myeloid 2Classical hematology 2

Conditions

Neuroendocrine Tumors 4Intestinal Neuroendocrine Tumor 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Data Collection × Endocrine × Clear all
NCT06876532 2025-11-18

LUTIBI

Institut Claudius Regaud

Phase NA Recruiting
150 enrolled
EndocrineNET

Intestinal Neuroendocrine Tumor

NCT05017662 2025-09-04

A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072

Ariceum Therapeutics GmbH

Phase NA Completed
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03562091 2020-08-28

OPERA

Ipsen

Completed
115 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03112694 2020-06-02

Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Ipsen

Completed
93 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03220087 2018-12-21

RECOSY

Ipsen

Completed
142 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡